NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor with an IC50 of 574 nM. It acts independently of Ca 2+ and inhibits Nigericin-induced inflammasome activation in THP-1 cells, as well as Imiquimod-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) [1].

In LPS-primed primary bone marrow-derived macrophages (BMDMs), the chemical NLRP3 inhibitor NLRP3-IN-NBC6 at a concentration of 10 μM and applied for 15 minutes, effectively suppresses the release of IL-1β triggered by Imiquimod. Additionally, NLRP3-IN-NBC6 fully blocks the secretion of NLRP3-dependent IL-1β in neutrophils. These neutrophils, sourced from both wild-type and NLRP3 knockout (KO) mouse bone marrow, were primed with LPS and subsequently treated with Nigericin in the presence of 10 μM NLRP3-IN-NBC6 [1].